Related Articles Even Market-Neutral Funds Couldn’t Escape the AI Slump in October Julie Segal It’s Biopharma or Bust for the IPO Market Stephen Taub Rethinking Diversification in a World Where Bonds May No Longer Be Enough Sponsored by Aspect Capital